Breaking News Instant updates and real-time market news.

CLDX

Celldex

$4.14

-0.06 (-1.43%)

17:27
10/09/16
10/09
17:27
10/09/16
17:27

Celldex reports Phase 2 data on glembatumumab vedotin in melanoma

Celldex Therapeutics presented results from the company's Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK inhibitor-refractory metastatic melanoma. The primary endpoint of the study -- 6 or more objective responses in the first 52 patients enrolled -- was exceeded. Seven of 62 patients experienced a confirmed response, and an additional 3 patients also experienced single timepoint responses. Median duration of response in this heavily pre-treated patient population was 6.0 months. 53% of patients experienced stable disease, with a minimum duration of six weeks. A 52% disease control rate was demonstrated. 52% of patients experienced tumor shrinkage. Median progression-free survival for all patients was 4.4 months. Patients who experienced rash in Cycle 1 experienced a 20% confirmed response rate and a more prolonged PFS of 5.5 months.

  • 09

    Oct

CLDX Celldex
$4.14

-0.06 (-1.43%)

03/08/16
JEFF
03/08/16
DOWNGRADE
Target $4
JEFF
Hold
Celldex downgraded to Hold with $4 target at Jefferies
Jefferies analyst Biren Amin last night downgraded Celldex Therapeutics to Hold from Buy and cut his price target for the shares to $4 from $31 following yesterday's Phase 3 trial failure of Rintega.
03/08/16
BMUR
03/08/16
NO CHANGE
Target $24
BMUR
Buy
Celldex valuation inexpensive ahead of catalysts, says Brean Capital
Brean Capital noted they removed Rintega from their Celldex model before the company announced they would discontinue their Phase 3 trial. The firm sees several upcoming catalysts in the second half of the year and believes shares can be valued substantially higher than the present value. Brean Capital reiterated its Buy rating and $24 price target on Celldex shares.
03/08/16
COWN
03/08/16
NO CHANGE
Target $12
COWN
Outperform
Celldex shares oversold, says Cowen
Cowen said it was extremely disappointing that the ACT lV pivotal study for Rintega would be stopped, driven by significant performance of the control arm. The firm believes Celldex shares are oversold and the remaining pipeline is undervalued. Cowen lowered its price target to $12 from $28 on Celldex shares and maintained its Outperform rating on the stock.
10/04/16
BMUR
10/04/16
INITIATION
Target $16
BMUR
Buy
Celldex assumed with a Buy at Brean Capital
Brean Capital analyst Jason Wittes assumed coverage of Celldex Therapeutics with a Buy rating and $16 price target.

TODAY'S FREE FLY STORIES

VNR

Vanguard Natural

$1.12

0.1083 (10.72%)

06:35
12/09/16
12/09
06:35
12/09/16
06:35
Downgrade
Vanguard Natural rating change  »

Vanguard Natural…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HDSN

Hudson Technologies

$7.33

0.01 (0.14%)

06:35
12/09/16
12/09
06:35
12/09/16
06:35
Syndicate
Hudson Technologies 6.429M share Secondary priced at $7.00 »

William Blair and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 09

    Dec

NVCR

Novocure

$8.75

0.4 (4.79%)

06:34
12/09/16
12/09
06:34
12/09/16
06:34
Conference/Events
Novocure to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

LFUS

Littelfuse

$154.58

3.1 (2.05%)

06:33
12/09/16
12/09
06:33
12/09/16
06:33
Earnings
Littelfuse backs Q4 adjusted EPS view $1.45-$1.59, consensus $1.52 »

Backs Q4 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

FLR

Fluor

$56.00

1.33 (2.43%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Upgrade
Fluor rating change  »

Fluor upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

$47.95

-0.4 (-0.83%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Upgrade
Gigamon rating change  »

Gigamon upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WNC

Wabash

$15.13

0.44 (3.00%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Initiation
Wabash initiated  »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$141.89

-3.09 (-2.13%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Initiation
Parker-Hannifin initiated  »

Parker-Hannifin initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$72.20

0.19 (0.26%)

, VLKAY

Volkswagen

$28.75

-0.188 (-0.65%)

06:32
12/09/16
12/09
06:32
12/09/16
06:32
Periodicals
Daimler CEO says company will be 2016's biggest luxury carmaker, Reuters says »

Daimler CEO Dieter…

DDAIF

Daimler AG

$72.20

0.19 (0.26%)

VLKAY

Volkswagen

$28.75

-0.188 (-0.65%)

BMWYY

BMW

$31.39

0.205 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jan

  • 10

    Jan

GWR

Genesee & Wyoming

$79.54

1.77 (2.28%)

06:31
12/09/16
12/09
06:31
12/09/16
06:31
Hot Stocks
Genesee & Wyoming reports November traffic up 3.7% y/y »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

06:30
12/09/16
12/09
06:30
12/09/16
06:30
Downgrade
DAVIDsTEA rating change  »

DAVIDsTEA downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WCN

Waste Connections

$76.63

0.04 (0.05%)

06:29
12/09/16
12/09
06:29
12/09/16
06:29
Upgrade
Waste Connections rating change  »

Waste Connections…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPR

Spirit AeroSystems

$61.26

0.65 (1.07%)

06:28
12/09/16
12/09
06:28
12/09/16
06:28
Downgrade
Spirit AeroSystems rating change  »

Spirit AeroSystems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADSK

Autodesk

$81.74

1.4 (1.74%)

06:26
12/09/16
12/09
06:26
12/09/16
06:26
Upgrade
Autodesk rating change  »

Autodesk upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

WEGRY

Weir Group

$11.65

-0.08 (-0.68%)

06:26
12/09/16
12/09
06:26
12/09/16
06:26
Downgrade
Weir Group rating change  »

Weir Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVRR

CVR Refining

$10.40

1.25 (13.66%)

06:25
12/09/16
12/09
06:25
12/09/16
06:25
Upgrade
CVR Refining rating change  »

CVR Refining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCS

Barclays

$11.99

0.09 (0.76%)

06:25
12/09/16
12/09
06:25
12/09/16
06:25
Downgrade
Barclays rating change  »

Barclays downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

PACCAR

$68.07

0.44 (0.65%)

06:24
12/09/16
12/09
06:24
12/09/16
06:24
Upgrade
PACCAR rating change  »

PACCAR upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSK

Oshkosh

$71.48

-0.07 (-0.10%)

06:23
12/09/16
12/09
06:23
12/09/16
06:23
Downgrade
Oshkosh rating change  »

Oshkosh downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTW

Manitowoc

$6.18

0.07 (1.15%)

06:22
12/09/16
12/09
06:22
12/09/16
06:22
Downgrade
Manitowoc rating change  »

Manitowoc downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMT

Kennametal

$34.21

0.16 (0.47%)

06:21
12/09/16
12/09
06:21
12/09/16
06:21
Downgrade
Kennametal rating change  »

Kennametal downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$57.29

0.01 (0.02%)

06:20
12/09/16
12/09
06:20
12/09/16
06:20
Periodicals
Wells Fargo names four board members for sales scandal review, Reuters reports »

Wells Fargo named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNCFF

UniCredit

$2.73

0.07 (2.63%)

06:20
12/09/16
12/09
06:20
12/09/16
06:20
Hot Stocks
UniCredit to sell 32.8% stake in Bank Pekao to PZN, PFR »

UniCredit announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ETN

Eaton

$68.98

0.08 (0.12%)

06:19
12/09/16
12/09
06:19
12/09/16
06:19
Upgrade
Eaton rating change  »

Eaton upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSGN

MSG Networks

$21.20

-0.45 (-2.08%)

06:18
12/09/16
12/09
06:18
12/09/16
06:18
Upgrade
MSG Networks rating change  »

MSG Networks upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.